Home Sleep Testing for Sleep Apnea

Home sleep testing (HST) offers a streamlined, lower-cost pathway for diagnosing obstructive sleep apnea outside of a clinical laboratory setting. This page covers how HST devices work, the regulatory framework governing their use, the clinical scenarios where HST is appropriate, and the boundaries that determine when a full in-lab study is required instead. Understanding these distinctions matters because misapplication of HST can result in missed diagnoses or delayed treatment for a condition affecting an estimated 30 million adults in the United States (American Academy of Sleep Medicine, 2014 prevalence estimates).

Definition and scope

Home sleep testing refers to a category of portable monitoring devices used to detect physiological signals associated with sleep apnea during sleep in a patient's own home. The Centers for Medicare & Medicaid Services (CMS) classifies these devices under the category of Home Sleep Apnea Tests (HSAT) and distinguishes them from full polysomnography by the number and type of signals recorded (CMS, Local Coverage Determination LCD L33718).

The American Academy of Sleep Medicine (AASM) further classifies portable sleep monitors into four device types based on channel count and autonomy:

Type I — Full polysomnography conducted in a laboratory; technician present; minimum 7 channels including EEG, EOG, chin EMG, airflow, respiratory effort, oximetry, and ECG.
Type II — Comprehensive portable polysomnography; minimum 7 channels; no technician required; used unattended.
Type III — Modified portable sleep apnea testing; 4–7 channels; typically includes airflow, respiratory effort, oximetry, and heart rate; the most common HST format in clinical practice.
Type IV — Continuous single- or dual-channel recording (most often oximetry alone); limited diagnostic utility for formal apnea diagnosis under current AASM guidelines.

For insurance reimbursement under Medicare, HST devices must meet CMS criteria, and results must be interpreted by a licensed physician or qualified non-physician practitioner as defined under 42 CFR Part 410.

How it works

A Type III HST device — the standard used in most diagnostic protocols — records a minimum of 4 physiological channels simultaneously. These channels typically include:

Nasal airflow via a pressure transducer or thermistor
Respiratory effort via thoracic and abdominal belts measuring chest wall movement
Pulse oximetry measuring blood oxygen saturation (SpO₂)
Heart rate or ECG

Some devices also incorporate body position sensors and snoring microphones, though these are not universally required. The device is worn overnight and returned to the prescribing provider or mailed to a processing center. Proprietary software performs an automated preliminary scoring, after which a board-certified sleep physician reviews and interprets the raw signal data to produce a diagnostic report.

The primary output metric is the Apnea-Hypopnea Index (AHI), defined as the number of apnea and hypopnea events per hour of recording time. Because HST measures recording time rather than true sleep time — a distinction from in-lab sleep study polysomnography — the AHI derived from HST may underestimate event frequency. AASM clinical practice guidelines acknowledge this systematic difference and recommend that interpreting physicians account for it when setting treatment thresholds.

Regulatory oversight of HST devices falls under the U.S. Food and Drug Administration (FDA), which classifies most portable sleep monitors as Class II medical devices subject to 510(k) premarket notification requirements under 21 CFR Part 882.

Common scenarios

HST is clinically appropriate in a defined range of presentations. AASM clinical guidelines published in the journal Journal of Clinical Sleep Medicine outline that HST is suitable when:

The patient presents with a high pretest probability of moderate-to-severe obstructive sleep apnea, including classic symptoms such as witnessed apneas, excessive daytime sleepiness, and a body mass index above 30 kg/m².
The patient does not have significant comorbid cardiorespiratory disease, neuromuscular disease, or other sleep disorders that would complicate interpretation.
Access to a sleep laboratory is restricted by geography, cost, or wait time — situations addressed in the broader regulatory context for sleep medicine services.
Follow-up HST is used to confirm treatment response, particularly to evaluate CPAP efficacy when CPAP and positive airway pressure therapy has been initiated.

HST is also used in occupational medicine contexts, particularly for commercial drivers subject to Federal Motor Carrier Safety Administration (FMCSA) guidance on obstructive sleep apnea screening, though FMCSA has not issued a formal federal rule mandating testing as of the most recent regulatory record.

Decision boundaries

HST is explicitly contraindicated or insufficient in clinical situations where in-lab polysomnography is required. The home sleep testing pathway is inappropriate when:

Central sleep apnea or complex sleep apnea is suspected, as HST devices cannot distinguish central from obstructive events without respiratory effort channels interpreted alongside EEG data.
Pediatric patients are involved — AASM guidelines do not support HST for children, and in-lab polysomnography remains the standard of care for this population.
Comorbid sleep disorders such as restless legs syndrome, periodic limb movement disorder, narcolepsy, or REM sleep behavior disorder are clinically suspected, as these require EEG and EMG channels not present in standard Type III devices.
A prior HST has returned a negative or technically inadequate result in a patient where clinical suspicion remains high. AASM guidance states that a negative HST does not rule out sleep apnea and warrants in-lab testing.
The patient has significant nocturnal hypoxemia from causes other than sleep-disordered breathing, including chronic obstructive pulmonary disease or congestive heart failure.

Familiarity with these decision thresholds — and with the full index of sleep medicine topics — supports accurate application of HST within a structured diagnostic pathway rather than as a universal screening tool.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)